Featuring perspectives from Dr Bob Li, including the following topics:
• Evolution of targeted therapy for HER2-altered non-small cell lung cancer (NSCLC) (0:00)
• Incidence and management of HER2 amplifications and mutations in NSCLC (10:45)
• Role of ErbB/HER protein family biology in lung cancer (19:03)
• Current and emerging roles of antibody-drug conjugates in lung cancer (33:43)
• Considerations for clinical trial participation and improving access to care for patients with cancer (55:08)
• Management of trastuzumab deruxtecan-associated interstitial lung disease (1:03:18)
• Future of HER2-targeted therapy in lung cancer and beyond (1:14:39)
CME information and select publications
Research To Practice | Oncology Videos